Navigation Links
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Date:11/24/2009

SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of John A. Orwin to its Board of Directors, effective November 19, 2009. Mr. Orwin is a 20-year sales and marketing veteran in the biopharmaceutical industry and has been instrumental in the launch of several important therapeutics.

Mr. Orwin currently serves as Senior Vice President, BioOncology Business Unit at Genentech, Inc., a wholly-owned member of the Roche Group. In this role he is responsible for marketing, sales, business unit and late stage pipeline brand management for the largest oncology portfolio in the United States. Mr. Orwin led the successful introduction of several indications for the blockbuster products Avastin®, Rituxan®, Herceptin®, and Tarceva® in the United States. He has also served as a member of the several governance committees between Genentech and Roche, Biogen Idec, and OSI Pharmaceuticals.

From 2001 to 2004, Mr. Orwin achieved increasing responsibility at Johnson & Johnson, up to Franchise Vice President, Oncology Franchise at Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P. His previous experience includes the positions of Senior Director, Oncology Marketing at Alza Pharmaceuticals (acquired by Johnson & Johnson); Vice President, Marketing at Sangstat Medical Corporation; Marketing Director, Asthma at Rhone-Poulenc Rorer Pharmaceuticals; and Product Manager, Schering Oncology/Biotech at Schering-Plough Corporation. He led the successful launch of Taxotere in the United States while at Rhone-Poulenc Rorer and Thymoglobulin for Sangstat Medical Corporation.

Jean-Jacques Bienaime, Chairman of the NeurogesX Board of Directors, commented, "On behalf of the NeurogesX board, I would like to welcome John as our newest director. John has a successful track record introducing new therapeutics to the market, and we look forward to his contributions and insights as we focus on the upcoming launch of Qutenza(TM) in the United States and Europe. Strong sales and marketing capabilities are the foundation for a successful product launch, and the addition of John to the Board of Directors will be of significant value as the board and management team work together to ensure the success of the Qutenza brand."

Mr. Orwin said, "Launching a new product creates a significant growth opportunity, and Qutenza has great potential to deliver substantial value to patients, physicians and NeurogesX. The board and management team have executed an impressive clinical and regulatory strategy for Qutenza on par with biopharmaceutical industry leaders. I look forward to joining the board and advising on the commercial infrastructure and upcoming launch."

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead

product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza(TM) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza(TM); the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; difficulties or delays in the launch and commercialization of Qutenza; and the outcomes of any submissions to the FDA for NeurogesX' products and product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


NeurogesX, Inc.              The Ruth Group
Stephen Ghiglieri            Sara Pellegrino (investors)
Chief Financial Officer      (646) 536-7002
(650) 358-3310               spellegrino@theruthgroup.com

                             Jason Rando (media)
                             (646) 536-7025
                             jrando@theruthgroup.com

SOURCE NeurogesX, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
2. NeurogesX Expands Commercial Operations Leadership Team
3. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
4. NeurogesX to Present at JMP Securities Healthcare Focus Conference
5. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
6. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
9. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
10. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):